Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832569 · ClinicalTrials.gov registry record · Early Phase 1
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
A Early Phase 1 study of Solid Tumors and Identified by NGS, PCR or IHC, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
- 7
- Study locations
NCT03832569: Active Early Phase 1 study of Solid Tumors and Identified by NGS, PCR or IHC, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03832569 is a Early Phase 1 study of Solid Tumors and Identified by NGS, PCR or IHC that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832569, a Early Phase 1 study of Solid Tumors and Identified by NGS, PCR or IHC, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find out how well it works to prevent cancer from coming back in people who have had a solid tumor surgically removed, but still have tumor cells in their blood. During the study, the participant will receive either the study drug or a placebo for as long as 12 months, or until the cancer comes back, or the side effects of the treatment become too severe.
Primary Outcome
Patients who have ctDNA clearance at 12 months will be considered responders, and patients who do not have ctDNA clearance at 12 months will be considered non-responders.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (7)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2027-02 |
| Phase | Early Phase 1 |
What the registry record for NCT03832569 still lists
NCT03832569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03832569 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03832569 about?
NCT03832569 is a clinical study titled "Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors". The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find out how well it works to prevent cancer from coming back in people who have had a solid tumor surgically removed, but still have tumor cells in their blood. During the study, the participant will receive ei...
What is the current status of trial NCT03832569?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2019-02-20. Estimated completion is 2027-02.
What conditions does trial NCT03832569 study?
This clinical trial studies the following conditions: Solid Tumors, Identified by NGS, PCR or IHC.
What interventions are being tested in trial NCT03832569?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03832569?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03832569 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03832569's enrollment target sits among peer trials
17 118th of 125 higher than 7 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
RECRUITING · Phase 4
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI